Merck Just Paid $400M for a Cancer Drug That Hasn't Been Tested in Humans
Merck just dropped $400 million on a cancer drug from a two-year-old Chinese biotech that hasn't been tested in humans. The deal says as much about Big Pharma's desperation as it does about China's explosive rise in drug discovery.
A $400 Million Check for a Drug Nobody's Swallowed Yet
Merck just wrote a $400 million check for a cancer drug that has never been inside a human body. Not a Phase 3 blockbuster. Not a Phase 1 darling with promising early data. A preclinical compound, tested only in cells and animals, developed by a two-year-old Chinese biotech most people have never heard of.
The company is SciBrunch Therapeutics, a Shanghai-based startup founded in 2024. The drug is SPR2015, an oral pill designed to block one of the most notorious villains in cancer biology. And the deal, which has already closed, could be worth up to $2.13 billion if development and commercialization milestones are hit.
So why is one of the world's biggest pharma companies betting this kind of money on something so early? The answer involves a protein that scientists have chased for decades, a ticking clock on Merck's best-selling drug, and a seismic shift in where the world's cancer drugs are coming from.
The "Undruggable" Target That Won't Stay Undruggable
KRAS is a protein that tells cells when to grow. When it mutates, it gets stuck in the "on" position, like a gas pedal jammed to the floor. The result: uncontrolled cell growth, a.k.a. cancer.
For 40 years, scientists called KRAS "undruggable." The protein's surface was too smooth, too slippery for traditional drugs to grab onto. That changed in 2021 when the first KRAS inhibitor (targeting a different mutation, G12C) finally reached patients. But KRAS G12D, the specific mutation SciBrunch is targeting, remains one of the biggest unsolved problems in oncology.
Why does G12D matter so much? It's one of the most common KRAS mutations found in pancreatic, colorectal, and lung cancers. Pancreatic cancer alone has a five-year survival rate of approximately 13%. A drug that can block KRAS G12D in its active ("ON") state could change the game for cancers that currently have terrible treatment options.
SPR2015 is described as a "molecular-glue" inhibitor, a clever approach that works by forcing two proteins to stick together in a way that shuts KRAS G12D down. Preclinical results show antitumor activity in cell and animal models, but that's it for now. No human safety data. No dosing information. No efficacy signal in actual patients.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Merck is essentially buying a lottery ticket. A very, very expensive lottery ticket.
Keytruda's Clock Is Ticking
This deal makes a lot more sense when you remember what's happening to Keytruda, Merck's crown jewel cancer immunotherapy. Keytruda is one of the best-selling drugs in history. It's also losing patent protection in 2028.
When that happens, cheaper copies will flood the market. Merck needs to fill the hole, and it needs to start now because drug development takes years. The SciBrunch deal is part of a deliberate strategy: go shopping for promising oncology assets, buy them early, and hope some of them turn into the next franchise.
Merck has been running this playbook aggressively. In 2024, it licensed LaNova Medicines' PD-1/VEGF bispecific antibody for $588 million upfront (total deal value: up to $3.3 billion). Before that, it struck a massive collaboration with Kelun-Biotech for antibody-drug conjugates worth up to $9.3 billion in potential value.
Notice a pattern? All three deals involve Chinese biotech companies.
China's Biotech Moment
A decade ago, the idea of a major U.S. pharma licensing a preclinical cancer drug from a Chinese startup would have raised eyebrows. Today, it's becoming routine.
The numbers tell the story clearly. The value of licensing deals for China-origin drug assets rose from about $5 billion in 2020 to over $50 billion in 2024. That's a tenfold increase in four years. By mid-2025, U.S. drugmakers had already signed 14 China-related deals worth $18.3 billion, and nearly half of all U.S. inbound licensing deals involved Chinese companies.
Pfizer jumped in too. In 2025, it paid $1.25 billion upfront to 3SBio for a cancer bispecific antibody, with total milestones reaching $4.8 billion and a total potential deal value exceeding $6 billion including an equity investment.
China isn't just a manufacturing hub anymore. It's becoming a drug discovery powerhouse, producing sophisticated, globally competitive molecules at a pace (and price point) that Western biotechs struggle to match. For Big Pharma, it's like discovering a new talent pool: why build everything in-house when you can license world-class science from Shanghai?
A Two-Year-Old Company With a $2 Billion Deal
SciBrunch's story is almost absurdly fast. Founded in 2024 by Tao Hu, PhD (a veteran of WuXi AppTec, Merck, and Amgen) and Yang Zhang, PhD (a medicinal chemist also from WuXi AppTec), the company raised about $65 million across an angel round and a pre-Series A led by HighLight Capital.
Two years later, it has a $2.13 billion deal with Merck. The company's pipeline is small but focused: SPR1020, a next-generation PARP1 inhibitor already in Phase 1/2 trials, and SPR2015, the KRAS drug Merck just licensed. A couple more programs sit in early discovery.
For SciBrunch, the Merck deal is transformational. The $400 million upfront payment alone dwarfs the company's total fundraising by more than six times. It's validation that a tiny Chinese biotech can produce molecules that the world's largest pharma companies want to own.
The Elephant in the Lab
Let's be clear about the risk here. SPR2015 has not been tested in a single human patient. Preclinical results in mice and cell cultures are encouraging, but the history of drug development is littered with compounds that looked brilliant in animals and failed spectacularly in people.
Merck is booking the $400 million as a pre-tax charge in Q3 2026, which tells you this is being treated as an R&D expense, not as an acquisition of a proven asset. The remaining $1.73 billion in milestones only gets paid if the drug actually works in clinical trials and eventually reaches the market.
That's the bet: Merck pays a premium for early access to a hot target, knowing full well that most preclinical drugs never make it. But if KRAS G12D cracks open, the payoff could be enormous across pancreatic, colorectal, and lung cancers.
What This Means for the Rest of Us
This deal is a signal flare, and it's pointing in two directions at once.
First, the KRAS race is heating up. Multiple companies are chasing G12D inhibitors, and Merck clearly didn't want to be left without a horse in that race. Paying $400 million for a preclinical asset suggests they believe the science is real and the window to buy is closing.
Second, the U.S.-China biotech pipeline is now a structural feature of the industry, not a temporary trend. Despite geopolitical tension and occasional regulatory scrutiny, the economic logic is too compelling for either side to walk away. Chinese biotechs get cash and global validation; American pharma gets innovative drugs faster and cheaper than building from scratch.
Whether SPR2015 eventually helps a single cancer patient remains an open question. But the fact that Merck bet $400 million on a two-year-old Shanghai startup's preclinical drug? That tells you everything about where drug innovation is heading.
4 min read
GSK Thinks It Can Build a Better Flu Shot With mRNA
GSK's mRNA flu vaccine just beat both standard and high-dose flu shots in a mid-stage trial of 971 adults. Now it's heading to Phase 3, putting GSK squarely in Moderna's rearview mirror in the race to reinvent the annual flu shot.
